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Background: To investigate the effects of inhaled beta-agonists on sub-maximal and maximal exercise capacity, breathing pattern,
dyspnoea, leg-discomfort and spirometry in patients with cystic fibrosis (CF).
Objectives: Eight patients performed two maximal incremental cycle-ergometry tests on separate days with inhaled placebo or salbutamol
(600 Ag) administered before each test in a randomized, double-blind, placebo-controlled crossover trial. Primary outcomes were exercise
duration (Exdur) in seconds (s) and maximal oxygen uptake (VO2max) in litres/minute (L/min). Forced expiratory volume in 1 s (FEV1) was
measured immediately pre-inhaler, post-inhaler and post-exercise. Dyspnoea and leg-discomfort were assessed post-exercise.
Results: Within-day FEV1 comparisons demonstrated that the placebo test day FEV1 improved significantly post-exercise (0.11 L, p <0.05)
and the salbutamol test day FEV1 improved significantly post-inhaler (0.22 L, p <0.001) and post-exercise (0.07 L, p <0.01). Between-day
FEV1 comparisons demonstrated significant improvements in post-inhaler (0.17 L, p <0.05) and post-exercise (0.13 L, p <0.05) FEV1
following salbutamol. Sub-maximal and maximal exercise showed no significant difference as shown by Exdur (547T154 s vs. 529T127 s)
and VO2max (1.9T0.5 L/min vs. 1.9T0.6 L/min). No significant change in breathing pattern, dyspnoea or leg-discomfort was detected. The
study had a power of 92% to detect a 10% improvement in Exdur.
Conclusions: In adults with CF, salbutamol improves post-exercise FEV1 and is safe when administered immediately before exercise but
does not improve exercise capacity, exercise-induced dyspnoea or leg-discomfort.
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Approximately 80% of patients with cystic fibrosis (CF)
are prescribed inhaled bronchodilators as part of routine
therapy [1,2]. There is no study assessing their effect on
maximal exercise capacity. Exercise is an important part of
activities of daily living for patients with CF and has
therapeutic effects on sputum clearance, respiratory muscle
strength and quality of life [3–5].1569-1993/$ - see front matter D 2005 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2004.11.004
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capacity in chronic obstructive airways disease (COPD)
[6]. They have also been shown to improve exertional
dyspnoea and dynamic hyperinflation during exercise
[7,8].
The current authors hypothesized that if bronchodilators
improve exercise capacity in CF they may also improve
these clinical and physiological outcome measures. This
study was a prospective double-blind randomized placebo-
controlled crossover trial using the short acting beta-agonist
salbutamol in patients recruited from the National Adult
Referral Centre for CF. We investigated whether an
improvement in FEV1 following beta-agonist therapy would
lead to a significant improvement in maximal or sub-4 (2005) 101 – 105ed by Elsevier B.V. All rights reserved.
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and leg-discomfort were also investigated since these are the
commonest symptoms of exercise cessation in CF [9].2. Methods
2.1. Subjects
Ten patients were recruited from the Adult National
Referral Center for CF. All had documented clinical,
radiological and genotypic features consistent with CF and
an abnormal sweat test (sweat sodium and chloride>60
mmol/L). Patients were assessed before the study and were
clinically stable with no change in cough or shortness of
breath, no requirement for oral or intravenous antibiotic
medication for four weeks before the study and no
significant change in spirometry compared to baseline
values. The study was approved by the Ethics Committee
of St. Vincent’s University Hospital and written informed
consent was obtained from all patients.
2.2. Study design
The study was a double-blind placebo-controlled cross-
over trial. Testing was conducted on two different days,
separated by at least 24 h (mean 3 days, range 1–7 days).
All patients were using inhaled bronchodilators before the
study which were stopped 48 h before the first exercise test.
Study inhalers were prepared by an attendant not involved
in the remainder of the protocol. Patients were instructed on
proper inhaler technique before each test. During admin-
istration six puffs were inhaled using a spacer device (giving
a dose of 600 Ag per patient). No patient took bronchodi-
lators between tests. Baseline measurements commenced
immediately following drug inhalation.
2.3. Exercise protocol
Exercise testing was carried out in an exercise labo-
ratory immediately after drug inhalation. The exercise
protocol was identical to that in used in previous
publications [10]. Patients were asked to avoid strenuous
activity for 24 h and food and caffeinated drinks for 2 h
before exercise testing. Testing was performed on an
electrically braked cycle ergometer (Excalibur, Lode BV,
Groningen, the Netherlands), with the patient breathing
room air. After inhaler administration patients put on a
nose clip and a mouthpiece connected to a recording
computer, and resting measurements were taken over 4 min
followed by a 2-min period of warm-up, which was set at a
15-W workload. This was followed by the incremental
phase in which the workload increased by 15-W/min in a
ramp fashion until exhaustion. With the use of speedometer
feedback, patients were instructed to pedal between 50 and
70 revolutions/min.Electrocardiogram leads were attached to the chest,
which enabled continuous monitoring of heart rate (HR).
Arterial oxygen desaturation (SaO2) was monitored using
pulse oximetry (SAT-TRAK Oximeter, Sensor Medics,
Yorba Linda, CA). Each patient’s mouthpiece was con-
nected to a heated wire flowmeter (Mass Flow Sensor,
Sensor Medics, Yorba Linda, CA). The flow signal was
digitally integrated to give tidal volume (Vt), and respired
gases were continually analysed by rapidly responding
oxygen (paramagnetic) and carbon dioxide (infrared)
analysers. All equipment was calibrated before each
exercise study using calibration syringes and precision
oxygen and carbon dioxide gas mixtures.
2.4. Spirometry
Spirometry was carried out on each patient using a
spirometer (Pneumocheck, Welch Allyn, Skaneatles Falls,
New York, USA). Forced expiratory volume in 1 s (FEV1)
and forced vital capacity (FVC) were obtained using
techniques described previously, and predicted normal
values were used to calculate percentage predicted values
[11,12]. At least three well co-coordinated maximal efforts
were obtained, and the highest value obtained was
recorded. Spirometry was assessed at three stages: imme-
diately pre-inhaler, within 1 min post-inhaler and within 1
min post-exercise.
2.5. Dyspnoea and leg-discomfort
Dyspnoea was assessed using the modified Borg scale.
The Borg Scale is a visual analog scale from 0 to 10 of
dyspnoea and leg discomfort (0=no breathlessness, no leg
discomfort, 10=maximal breathlessness, maximal leg dis-
comfort) that has been validated during exercise [13].
Dyspnoea was assessed in response to the question, ‘‘How
breathless do you feel?’’ with the subject pointing to the
appropriate number on the scale. Leg-discomfort was
assessed using the Borg scale, in response to the question,
‘‘How much leg-discomfort do you feel?’’. Patients were
familiarized with the scale before testing.
2.6. Data analysis
Maximum oxygen uptake, maximum carbon dioxide
output (VCO2max), minute ventilation (Ve), Vt, respiratory
frequency (F) and HR and were measured breath by breath
using standard formulas [14,15]. Minute ventilation and Vt
were expressed at body temperature and pressure, oxygen
uptake and VCO2 were expressed at standard temperature
and pressure. Predicted VO2max was calculated as follows:
predicted VO2max = 0.83ht2.7 (10.007age)
(10.25S), where height (ht) is in meters, age is in
years, and S represents gender (S =0 for men and S =1 for
women [14]. Predicted maximum HR was calculated as
follows: predicted maximum HR=210 (0.66age) [14].
Table 2
End-exercise measurements (meanTSD)
Exercise measurement Placebo Salbutamol
Wmax (W) 151T39 147T33
Exdur (s) 547T154 529T127
VO2max (L/min) 1.9T0.5 1.9T0.6
VCO2max (L/min) 2.2T0.6 2.2T0.5
Ve (L/min) 65.0T16 64.5T15
F (breaths/min) 47T10 47T11
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Results are shown as the meanT standard deviation (SD).
Within and between-day mean spirometry, mean matched
sub-maximal workloads and end-exercise comparisons were
compared using ANOVA for repeated measures [16]. The
Borg scale was analyzed using Wilcoxon’s signed rank test.
p <0.05 was considered significant for all calculations.Vt (L) 1.5T0.5 1.4T0.5
SaO2 (%) 94.5T3 94.1T4
HR (bpm) 164T16 167T13
Borg-Dyspnoea 3.8T2.2 4.0T2.5
Borg-leg discomfort 5.0T2.7 4.8T2.8
Wmax—maximum workload; Exdur—exercise duration; VO2max—max-
imum oxygen uptake; VCO2—maximum carbon dioxide output; Ve—
minute ventilation; F—respiratory frequency; Vt—tidal volume; SaO2—
oxygen desaturation; HR—heart rate; bpm—beats per minute.3. Results
Two patients were excluded from all analyses, one because
of a non-maximal effort exercise test and another because of a
respiratory tract infection requiring antibiotics between test
days. There were no complications from exercise testing and
mean data at rest for both test days revealed no significant
differences in baseline measurements or spirometry.
Mean FEV1 was 52% predicted and mean FVC was 75%
predicted indicating a group of patients with moderate CF
lung disease (Table 1). Mean VO2max was 64% predicted
indicating moderate exercise impairment.
Mean end-exercise measurements for each test day
showed no statistically significant difference in any of the
measured variables (Table 2). A post-hoc analysis of the
current study data showed it sufficient to detect a 10%
increase in exercise duration (55 s) with a power of 92%.
Within-day FEV1 comparisons on the placebo test
day showed no significant change post-inhaler (2.11T0.8
vs. 2.13T0.85) but improved significantly post-exercise
(2.13T0.85 vs. 2.24T0.9, p <0.05). The salbutamol test
day FEV1 increased significantly post-inhaler (2.08T0.81
vs. 2.30T0.88, p <0.001) and post-exercise (2.30T0.88 vs.
2.37T0.9, p <0.05).
Between-day FEV1 comparisons showed that resting pre-
inhaler FEV1 showed no statistically significant difference
(2.11T0.8 vs. 2.08T0.8). Post-inhaler and post-exercise
FEV1 showed significant improvements (2.13T0.85 vs.
2.30T0.88, p <0.05) and 2.24T0.9 vs. 2.37T0.9, p <0.05)
respectively on the salbutamol test day.
Resting, sub-maximal and maximal group mean exercise
measurements on both test days demonstrated a progressive
rise in VO2, VCO2, Ve, Vt, f and HR during exercise.Table 1
Characteristics of the study group (meanTSD)
Age (years) 24T7
Gender 7M, 1F
Genotype 7 DF508 homozygous,
1 DF508/NI303K
FEV1 (% predicted) 52T18
FVC (% predicted) 75T18
FEV1/FVC % 67T11
VO2max (% predicted) 64T14
Maximum HR (% predicted) 84T8
FEV1—forced expired volume in one second; FVC—forced vital capacity;
VO2max—maximum oxygen uptake; HR—heart rate.PetCO2 also showed a significant increase during exercise.
No significant differences were seen in any of the variables
at rest or during sub-maximal workloads. There was a
similar fall in SaO2 on both test days. There was no
alteration in breathing pattern between placebo and salbu-
tamol studies. Salbutamol did not reduce the sense of
dyspnoea or leg-discomfort at end-exercise.4. Discussion
The main findings from this study are that in adults with
CF, beta-agonists taken immediately before exercise (i)
improve post-exercise FEV1, (ii) do not improve exercise
capacity, (iii) do not improve exercise-induced dyspnoea or
leg-discomfort and (iv) do not have any clinically adverse
effects during exercise.
In this study the increase in FEV1 following salbutamol
did not lead to an improvement in exercise capacity. There
are several possible explanations for this. Although respi-
ratory factors are thought to play the primary role in exercise
limitation other factors are known to contribute. Arterial
desaturation, peripheral muscle dysfunction, nutritional and
cardiac factors have all been shown to influence exercise
capacity in CF [1,2]. While beta-agonists may affect cardiac
function the current authors think this was unlikely in the
current study as there were no significant differences in
submaximal or maximal HR between placebo and salbuta-
mol tests. To our knowledge, beta-agonists have no known
influence on peripheral muscle function or nutrition as
contributory factors in exercise limitation in CF. If exercise
capacity was purely limited by respiratory factors the
significant bronchodilation seen in this group should have
lead to an improvement in exercise capacity. The current data
showed no significant differences in any measured parameters.
Several studies have shown improvements in exercise
capacity and reductions in dynamic hyperinflation in
COPD following h2-agonists [17–19]. Results have not
been consistent in all studies however. One study did not
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terbutaline inhalation, but did find significant improve-
ments in FEV1 and VO2max contribution to exercise
limitation COPD. The effect of bronchodilators in asthma
has also been studied. One study demonstrated that beta-
agonists increase FEV1 but do not improve exercise
capacity [20].
Several studies have shown improvements in FEV1
following bronchodilators in CF but some studies have
suggested a detrimental influence on overall lung function.
One study suggested inhaled bronchodilators might
decrease bronchial wall tone in large central airways at rest
leading to airway collapse during forced expiratory maneu-
vers [21]. This may lead to an increase in FEV1 but a
paradoxical decrease in expiratory flows in peripheral
airways in the lung. These changes could be even further
accentuated during exercise. A larger study in 92 patients
found somewhat similar findings but the paradoxical
changes in airflow were very small and uncommon [22].
Another study showed that beta-agonists reduce hypoxia-
induced bronchoconstriction and caused venous admixture
in patients with COPD at rest resulting in ventilation/
perfusion mismatching and a decrease in PaO2 [23]. Finally,
one study assessed the effect of bronchodilators at sub-
maximal workloads in CF [24]. That study showed an
increase in physiological dead space, ventilation, ventilatory
equivalent for oxygen (Ve/VO2) and end-expiratory oxygen
pressure following one week of nebulized salbutamol.
These effects were seen at low workloads (1/3 Wmax) with
combination therapy (nebulized salbutamol and theophy-
line). Dyspnoea and leg-discomfort were not measured. The
current study showed no changes in Ve, Ve/VO2, PetCO2 or
any other exercise variable during sub-maximal or maximal
exercise following inhaled salbutamol and no clinically
significant adverse events. We also could not detect any
significant difference in oxygen desaturation between
control and salbutamol tests during sub-maximal or
maximal workloads.
This is the first study assessing the effect of beta-
agonists on maximal exercise capacity and exercise-
induced symptoms in CF. Many CF patients are prescribed
and use bronchodilators before or during exercise with no
systematic evaluation under maximal exercise conditions.
Since we could find no improvement in exercise capacity
or exercise-induced symptoms in the current analysis the
routine use of bronchodilators before exercise may be
questioned. Patients with active lifestyles should be
individually assessed for objective improvements in
exercise performance or exercise-induced symptoms.
There are some limitations to the current study. The
absolute increase in FEV1 on the salbutamol test day
although statistically significant was small following
exercise. Such a small effect might not result in an
improvement in exercise capacity. It is possible that larger
inhaled doses or nebulized administration may have lead
to increased bronchodilation and possibly in exercisecapacity. However the current study protocol was delib-
erately chosen to mimic a typical dose and method of
administration commonly used in activities of daily living
by most CF patients since this is most likely to be applied
and adhered to in daily practice. Also everyday fitness
and the ability to train regularly may relate more
accurately to endurance capacity rather than to maximal
exercise capacity. When maximal and sub-maximal work
rates are compared, endurance capacity at the same
relative workload for a group of patients with CF,
expressed as a percentage of VO2max, is unimpaired
compared to controls [25]. In spite of a limit to maximal
performance imposed by lung function, patients with CF
have a good capacity for endurance exercise when the
workload is prescribed relative to their maximal workload
or VO2 max. Therefore beta-agonists may have an effect
on exercise-induced symptoms during endurance exercise
not detected with a maximal incremental exercise proto-
col. Finally, the number of patients in this study is small.
It is possible that a larger cross-sectional study, perhaps
using a multidrug regimen may show improvements in
exercise capacity or exertional dyspnoea following bron-
chodilators that were not detected in our group using a
single drug regimen. Until such a study is performed we
feel there is no general evidence to support the use of a
single drug regimen bronchodilator during exercise in
adults with CF.
In conclusion in adults with CF salbutamol (i) improves
FEV1 following exercise, (ii) does not effect sub-maximal or
maximal exercise capacity or breathing pattern, (iii) does not
improve dyspnoea or leg-discomfort and (iv) appears safe
when administered immediately before exercise.Acknowledgements
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